Drug Trial Radar · NCT05201781
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
295
Planned (sponsor's estimate)
Start
Mar 9, 2022
Primary completion
Jul 29, 2037
Study completion Jun 30, 2041
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Conditions
- Multiple Myeloma
Interventions
Cilta-celDrug
Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with New Malignancies and Recurrence of Pre-existing MalignancyTime frame: Up to 15 years
- Number of Participants with New Incidence or Exacerbation of a Pre-existing Neurologic DisorderTime frame: Up to 15 years
- Number of Participants with New Incidence or Exacerbation of a Pre-existing Rheumatologic or Other Autoimmune DisorderTime frame: Up to 15 years
- Number of Participants with New Incidence of Grade Greater than or Equal to (>=) 3 Hematologic Disorder Including HypogammaglobulinemiaTime frame: From year 1 up to year 5
- Number of Participants with Serious Hematologic Disorder, including HypogammaglobulinemiaTime frame: From year 6 up to year 15
- Number of Participants with New Incidence of Grade >= 3 InfectionTime frame: From year 1 up to year 5
- Number of Participants with Serious InfectionTime frame: From year 6 up to year 15
- Number of Participants with Serious Adverse Events (SAEs)Time frame: From year 1 up to year 5
- Number of Participants with Related Serious Adverse Events Assessed by the InvestigatorTime frame: From year 6 up to year 15
Locations
50 sites in 8 countries. Site status is shown where the registry gives one.
Mayo Clinic Cancer Center-Scottsdale
Phoenix, Arizona · Recruiting
City of Hope
Duarte, California · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
Stanford University Medical Center
Stanford, California · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
Indiana University
Indianapolis, Indiana · Recruiting
Kansas University Medical Center
Westwood, Kansas · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
Washington University School Of Medicine
St Louis, Missouri · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
Roswell Park Cancer Institute
Buffalo, New York · Recruiting
Mount Sinai Medical Center
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
Levine Cancer Institute
Charlotte, North Carolina · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Froedtert Memorial
Milwaukee, Wisconsin · Recruiting
UZ Gent
Ghent, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Peking University Third Hospital
Beijing, China · Active not recruiting
West China Hospital Si Chuan University
Chengdu, China · Active not recruiting
Fujian Medical University Union Hospital
Fuzhou, China · Active not recruiting
Sun Yat-sen University Cancer Hospital
Guangzhou, China · Active not recruiting
First Hospital, Zhejiang University Medical College
Hangzhou, China · Active not recruiting
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
Nanjing, China · Active not recruiting
Jiangsu Province Hospital
Nanjing, China · Active not recruiting
Shanghai Changzheng Hospital
Shanghai, China · Active not recruiting
Ruijin Hospital Shanghai Jiao Tong University
Shanghai, China · Active not recruiting
Shanghai Fourth People s Hospital
Shanghai, China · Active not recruiting
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.